Low-dose <i>i</i>nterleukin 2 for the reduction of <i>v</i>ascular inflammati<i>o</i>n in acute corona<i>ry</i> syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial.

ABSTRACT:

Introduction

Inflammation plays a critical role in the pathogenesis of atherosclerosis, the leading cause of ischaemic heart disease (IHD). Studies in preclinical models have demonstrated that an increase in regulatory T cells (Tregs), which have a potent immune modulatory action, led to a regression of atherosclerosis. The Low-dose InterLeukin 2 (IL-2) in patients with stable ischaemic heart disease and Acute Coronary Syndromes (LILACS) study, established the safety of low-dose IL-2 and its biological efficacy in IHD. The IVORY trial is designed to assess the effects of low-dose IL-2 on vascular inflammation in patients with acute coronary syndromes (ACS).

Methods and analysis

In this study, we hypothesise that low-dose IL-2 will reduce vascular inflammation in patients pre

SUBMITTER: Sriranjan R 

PROVIDER: S-EPMC9558794 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature